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When biomarker concentrations of all patient samples were plot-
ted in chronological order of assaying, it appeared that there
was a sufﬁcient window of variation within a positively skewed
distribution. In general there was no evident variation over time
and between assays, except for two remarkable observations:
For the sCOMP assay there was a clear difference in measured
biomarker concentrations between the ﬁrst 6 kits and last 8 kits.
In the ﬁrst kits measured biomarker concentrations were a 10-fold
higher and showed signiﬁcantly more variation than in the last
kits. For the sC1,2C and sCS846 assays, there was a signiﬁcant
negative correlation between the measured biomarker concentra-
tion and sample order (chronologic/position) in the assay plates,
repeatedly found for each of the assay plates.
Conclusions: Reliable biomarker measurement in this large sam-
ple set seems possible for the majority of the studied biomarkers.
However, despite attempts to minimize variation, there are some
striking challenges, presumably technical in nature. The remark-
able observations in the sCOMP assay, and the sC1,2C and
sCS846 assays need further evaluation (as is presently ongoing)
before correlations with the clinical and radiographic data sets can
be made.
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Purpose: 1) To determine the association of 31 biomarkers with
pre-radiographic and radiographic symptomatic knee OA com-
pared to symptomatic controls; 2) to determine if latent biomarker
factors determined by principal components based factor analy-
sis (PC-FA) are better able to distinguish OA stage compared to
individual biomarkers. PC-FA, in addition to revealing potential un-
derlying factors, may be useful to overcome problems of multiple
comparisons and may help stabilize variance.
Methods: 255 subjects, 40-79 years, with knee pain were as-
sembled, stratiﬁed by age decade and gender, in a cross-sectional
population-based study and evaluated with MRI, xray and biomark-
ers. MR cartilage (MRC) defects (score 0-4) and x-rays (Kellgren-
Lawrence [KL] grade 0-4) were read blinded. Subjects were
classiﬁed as No OA (NOA) (KL<2, MRC=0), Pre-Radiographic
OA (PROA) (KL<2, MRC≥1) or Radiographic OA (ROA) (KL≥2,
MRC≥1). Serum levels of matrix metalloproteinases (MMPs) 1, 3
and 9, tissue inhibitor of MMP, interleukins 1a, 1b, 4, 6, 7, 8, 10,
17A, tumor necrosis factor, c-telopeptide of type I collagen (CTX-I),
adiponectin, resistin, eotaxin, C-reactive protein, hyaluronic acid
(HA) and other cytokines were evaluated. PC-FA was performed
using individual biomarkers and ratios of markers previously mea-
sured, including urine c-telopeptide of type II collagen (uCTX-II),
urine and serum type II and types I and II collagen cleavage
neoepitopes (C2C and C1,2C respectively), c-propeptide of type
II procollagen (CPII), 846 epitope, and urine n-telopeptide of type
I collagen (uNTX-I). Multicategory logistic regression (adjusted for
age, sex and BMI) was used to evaluate the association of OA cat-
egory with each log transformed biomarker, biomarker ratio, and
biomarker factor, incorporating stratum sampling weights. Stan-
dardized (i.e. per standard deviation change) odds ratios (ORs)
were reported to enable comparison of the ORs across biomarker
variables.
Results: Signiﬁcant associations with PROA vs NOA were seen
for MMP-9 (OR 1.60, 95% CI 1.00-2.57), uC2C (OR 2.34, 95% CI
1.34-4.09), uC1,2C (OR 1.99, 95% CI 1.24-3.19), and uC2C/sCPII
ratio (OR 2.41, 95% CI 1.33-4.37). Risk of ROA vs NOA was
signiﬁcantly increased for uCTX-II (OR 2.97, 95% CI 1.45-6.08),
uC2C (OR 2.28, 95% CI 1.23-4.22), uC1,2C (OR 2.08, 95%
CI 1.21-3.56), uCTX-II/sCPII (OR 2.62, 95% CI 1.35-5.06) and
uC2C/sCPII (OR 2.55, 95% CI 1.32-4.95). PC-FA identiﬁed 4 clin-
ically interpretable factors, of which one factor (determined largely
by uCTX-II, uC2C, uNTX-I, CTX-I, uC1,2C, and HA) was signif-
icantly associated with PROA (OR 2.08, 95% CI 1.04-4.14) and
with ROA (OR 2.52, 95% CI 1.22-5.20). PC-FA with inclusion of
biomarker ratios resulted in similar ﬁndings. The strength of asso-
ciation with PROA and ROA was similar for individual biomarkers,
biomarker ratios and biomarker factors.
Conclusions: In this population-based study, several biomark-
ers were signiﬁcantly associated with PROA (MMP-9, uC2C and
uC1,2C), and with ROA (uCTX-II, uC2C, uC1,2C). Discrimination
of OA groups within this cohort was not improved using biomarker
factors (determined by factor analysis) over individual biomarkers
or biomarker ratios.
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Purpose: Tenascin-C (TN-C) is a modular, multifunctional,
hexabrachion-shaped, elastic extra cellular matrix (ECM) glyco-
protein with binding sites for other ECM proteins. It was discovered
originally at the myotendinous junction and later found in the os-
teotendinous junction and superﬁcial layers of articular cartilage.
It plays a major role in cell adhesion & migration, and stretches
several times its resting length due to its ﬁbronectin type (FN) III
domain. TN-C is abundantly expressed in musculoskeletal tissues
during organogenesis and embryogenesis, its expression is very
restricted in healthy tissues, and reappears as a high molecular
weight splice variant in association with wound healing, inﬂamma-
tory processes, or neoplasia. TN-C has been reported to be highly
reexpressed in cartilage in diseased/injured joints. The objective
of this study was to evaluate the potential of TN-C as a marker of
joint disease/injury.
Methods: TN-C high molecular weight variants that include FN
III A-D domains were speciﬁcally detected in synovial ﬂuid (SF)
samples by the Tenascin-C Large ELISA (IBL). Human SF from
patients with end stage osteoarthritis (OA, 28), rheumatoid arthri-
tis (RA, 8), anterior cruciate ligament rupture (ACL, 8), and
knee-healthy reference subjects (Ref, 24) from NEBH/Northland
Labs/NEBH/NDRI &Northland Labs, respectively were tested in
the assay. Joint instability surgery was performed in male cross-
bred hounds, right knee had a mini-arthrotomy and anterior cruci-
ate ligament transected (ACLT), and the contralateral limb had a
’sham’ surgery with a miniarthrotomy but no generation of instabil-
ity. At 1, 3 and 6 months post-surgery, 4-6 animals per timepoint
were euthanized, and SF collected from ACLT/sham knees. Joint
instability was induced in rats (n=4-6 per group) by medial menis-
cal surgery in one knee with the other knee as a contralateral
control. SF lavage samples collected at 1, 4, and 8 wks post
surgery.
Results: TN-C levels were signiﬁcantly elevated in SF from OA (7-
fold), RA (5-fold), and ACL (3-fold) human patients as compared to
reference individuals. There was a concomitant increase in TN-C
levels in human OA cartilage (>60-fold) as compared to non-OA
